Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,284 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial.
Naismith RT, Cohen JA, Bar-Or A, Comi G, Selmaj KW, Hartung HP, Sheffield JK, Krakovich A, Tatosian D, Cheng CY, Reardon J, Khaychuk V, Riolo JV, Silva D, Cree BA. Naismith RT, et al. Among authors: silva d. Mult Scler. 2024 Feb;30(2):177-183. doi: 10.1177/13524585231216854. Epub 2023 Dec 21. Mult Scler. 2024. PMID: 38130041 Free PMC article.
Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS.
Zivadinov R, Medin J, Khan N, Korn JR, Bergsland N, Dwyer MG, Chitnis T, Naismith RT, Alvarez E, Kinkel P, Cohan S, Hunter SF, Silva D, Weinstock-Guttman B; MS-MRIUS investigators. Zivadinov R, et al. Among authors: silva d. J Neuroimaging. 2018 Jul;28(4):399-405. doi: 10.1111/jon.12518. Epub 2018 May 11. J Neuroimaging. 2018. PMID: 29749661
Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study.
Zivadinov R, Medin J, Khan N, Korn JR, Chitnis T, Naismith RT, Alvarez E, Dwyer MG, Bergsland N, Carl E, Silva D, Weinstock-Guttman B; MS-MRIUS Study Group. Zivadinov R, et al. Among authors: silva d. Mult Scler Relat Disord. 2019 Jan;27:65-73. doi: 10.1016/j.msard.2018.09.037. Epub 2018 Oct 3. Mult Scler Relat Disord. 2019. PMID: 30342416
Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS.
DeLuca J, Schippling S, Montalban X, Kappos L, Cree BAC, Comi G, Arnold DL, Hartung HP, Sheffield JK, Liu H, Silva D, Cohen JA. DeLuca J, et al. Among authors: silva d. Mult Scler Relat Disord. 2021 Feb;48:102673. doi: 10.1016/j.msard.2020.102673. Epub 2020 Dec 10. Mult Scler Relat Disord. 2021. PMID: 33454584 Free article. Clinical Trial.
DeepGRAI (Deep Gray Rating via Artificial Intelligence): Fast, feasible, and clinically relevant thalamic atrophy measurement on clinical quality T2-FLAIR MRI in multiple sclerosis.
Dwyer M, Lyman C, Ferrari H, Bergsland N, Fuchs TA, Jakimovski D, Schweser F, Weinstock-Guttmann B, Benedict RHB, Riolo J, Silva D, Zivadinov R. Dwyer M, et al. Among authors: silva d. Neuroimage Clin. 2021;30:102652. doi: 10.1016/j.nicl.2021.102652. Epub 2021 Mar 29. Neuroimage Clin. 2021. PMID: 33872992 Free PMC article.
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Cree BA, Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Minton N, Cheng CY, Silva D, Kappos L, Cohen JA. Cree BA, et al. Among authors: silva d. Mult Scler. 2022 Oct;28(12):1944-1962. doi: 10.1177/13524585221102584. Epub 2022 Jun 28. Mult Scler. 2022. PMID: 35765217 Free PMC article. Clinical Trial.
Therapy effect on AI-derived thalamic atrophy using clinical routine MRI protocol: A longitudinal, multi-center, propensity-matched multiple sclerosis study.
Jakimovski D, Silva D, Niels Bergsland, Dwyer MG, Weinstock-Guttman B, Benedict RH, Riolo J, Zivadinov R; DeepGRAI Registry Study group. Jakimovski D, et al. Among authors: silva d. Mult Scler Relat Disord. 2023 Jun;74:104708. doi: 10.1016/j.msard.2023.104708. Epub 2023 Apr 9. Mult Scler Relat Disord. 2023. PMID: 37084495
Thalamic atrophy and dysconnectivity are associated with cognitive impairment in a multi-center, clinical routine, real-word study of people with relapsing-remitting multiple sclerosis.
Zivadinov R, Bergsland N, Jakimovski D, Weinstock-Guttman B, Lorefice L, Schoonheim MM, Morrow SA, Ann Picone M, Pardo G, Zarif M, Gudesblatt M, Nicholas JA, Smith A, Hunter S, Newman S, AbdelRazek MA, Hoti I, Riolo J, Silva D, Fuchs TA, Dwyer MG, Hb Benedict R. Zivadinov R, et al. Among authors: silva d. Neuroimage Clin. 2024;42:103609. doi: 10.1016/j.nicl.2024.103609. Epub 2024 Apr 27. Neuroimage Clin. 2024. PMID: 38718640 Free PMC article.
6,284 results